Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Pauli C, Puca L, Mosquera JM, Robinson BD, Beltran H, Rubin MA, et al. An emerging role for cytopathology in precision oncology. Cancer Cytopathol. 2016;124(3):167-73.

Yuan Z, Claros CS, Suzuki M, Maggi EC, Kaner JD, Kinstlinger N, et al. Loss of MEN1 activates DNMT1 implicating DNA hypermethylation as a driver of MEN1 tumorigenesis. Oncotarget. 2016;7(11):12633-50.

Rennert H, Eng K, Zhang T, Tan A, Xiang J, Romanel A, et al. Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. NPJ Genom Med. 2016;1.

Haka AS, Barbosa-Lorenzi VC, Lee HJ, Falcone DJ, Hudis CA, Dannenberg AJ, et al. Exocytosis of macrophage lysosomes leads to digestion of apoptotic adipocytes and foam cell formation. J Lipid Res. 2016;57(6):980-92.

Carden MA, Caltharp S, Yee ME, Haight AE, Westblade LF, Park S. Recipient-derived EBV-positive Monomorphic Plasmacytoma Type Posttransplant Lymphoproliferative Disorder After Allogeneic Stem Cell Transplant for Severe Aplastic Anemia: A Case Report. J Pediatr Hematol Oncol. 2016;38(8):e310-e314.

Inayat F, Law JK, Myers-Gurevitch PM, Seshan SV, Perlman AS. Minimal change disease: an unusual presentation of marginal zone MALT lymphoma. Clin Nephrol. 2016;85(3):184-8.

Calero-Cuenca FJ, Espinosa-Vázquez JM, Reina-Campos M, Diaz-Meco MT, Moscat J, Sotillos S. Nuclear fallout provides a new link between aPKC and polarized cell trafficking. BMC Biol. 2016;14:32.

Pizzi M, Covey S, Mathew S, Liu Y-, Ruan J, Leonard JP, et al. Hepatosplenic T-Cell Lymphoma Mimicking Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2016;16(3):e47-50.

Serra S, Vaisitti T, Audrito V, Bologna C, Buonincontri R, Chen S-, et al. Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. Blood Adv. 2016;1(1):47-61.

Trasino SE, Tang X-, Jessurun J, Gudas LJ. A retinoic acid receptor β2 agonist reduces hepatic stellate cell activation in nonalcoholic fatty liver disease. J Mol Med (Berl). 2016;94(10):1143-1151.